Opinion|Videos|December 29, 2023
Advancements in Squamous NSCLC Treatment: Subgroup Analysis from EMPOWER-Lung Trials
Author(s)Eduardo Santos, MD, FACP, FCCP
Eduardo Santos, MD, FACP, FCCP, delves into advancements in the treatment of squamous NSCLC, emphasizing crucial insights from the EMPOWER-Lung01 and EMPOWER-Lung03 subgroup analysis.
Advertisement
Episodes in this series
Advertisement
Related to this article
Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.
Sanja Dacic, MD, PhD, outlines advances that are reshaping molecular profiling in advanced non–small cell lung cancer and how to navigate these changes.
Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
3
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
4
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
5